• Cadrenal Therapeutics named John P. Sharp interim CFO on June 25, replacing Quang X. Pham.
• Sharp is a senior director at Lohman & Associates; he has served as CFO at several biopharma companies since 2007.
• He has been CFO of Skye Bioscience since March 31, 2026; previously CFO at SaNOtize and PhaseBio Pharmaceuticals.
• Board member Steven Zelenkofske resigned effective June 30; the departure was not tied to any disputes.
• Director Glynn Wilson shifted to Class III; he also joined the compensation committee and remained on audit and governance committees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-073213), on June 29, 2026, and is solely responsible for the information contained therein.